Barclays
LABU icon

Barclays’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Barclays’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500
Closed -$83K – 5503
2026
Q1 		$83K Sell
500
-5,100
-91% -$837K ﹤0.01% 4104
2025
Q4 		$893K Buy
+5,600
New +$769K ﹤0.01% 3512
2024
Q2 		– Sell
-136,900
Closed -$18.2M – 5112
2024
Q1 		$18.2M Sell
136,900
-14,715
-10% -$1.92M 0.01% 1037
2023
Q4 		$18.5M Buy
+151,615
New +$11.6M 0.01% 1097
2022
Q3 		– Sell
-65
Closed -$9K – 4983
2022
Q2 		$9K Hold
65
– – ﹤0.01% 4666
2022
Q1 		$20K Buy
65
+55
+550% +$20.7K ﹤0.01% 4442
2021
Q4 		$7K Buy
10
+6
+150% +$5.74K ﹤0.01% 4013
2021
Q3 		$4K Buy
+4
New +$4.92K ﹤0.01% 4624

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $1.14B AUM 79.59% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
EFG
Ethos Financial Group King Of Prussia, Pennsylvania $1.5B AUM 22.75% 1-Year Est. Return

Barclays's LABU Position: Q2 2026 in Review

Barclays sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q2 2026, closing a stake of 500 shares — an estimated $83K sold.

Barclays first reported a position in LABU in Q3 2021 and held it in 8 quarters. The position peaked at $18.5M in Q4 2023. 36 funds tracked by Wall St. Rank hold LABU as of Q2 2026.

  • Barclays reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q2 2026 after selling out during the quarter.
  • Barclays sold 500 Direxion Daily S&P Biotech Bull 3X ETF shares in Q2 2026, an estimated $83K.
  • Barclays first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2021 and held it in 8 quarters.
  • Barclays's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $18.5M in Q4 2023.
  • 36 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.